Review article · 2021 · Open access

Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges

Marinna Madrid, Cenk Sumen, Suvi Aivio, Nabiha Saklayen

Current Protocols, 1(3), e88 · Published 1 March 2021 · DOI 10.1002/cpz1.88

Open PDFView at the publisherCite this paper

In brief

“Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges” is a 2021 review article by Marinna Madrid and 3 co-authors, published in Current Protocols. OpenAlex counts 126 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Current Protocols.

Citations
126
Most cited in
2023 (35)
Field-weighted impact
1.89
References
158
Authors
4

Abstract

The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as a starting material for autologous, or patient-specific, stem cell-based therapies. Since the first publications describing the generation of iPSCs from human tissue in 2007, a Phase I/IIa clinical trial testing an autologous iPSC-derived cell therapy has been initiated in the U.S., and several other autologous iPSC-based therapies have advanced through various stages of development. Three single-patient in-human transplants of autologous iPSC-derived cells have taken place worldwide. None of the patients suffered serious adverse events, despite not undergoing immunosuppression. These promising outcomes support the proposed advantage of an autologous approach: a cell therapy product that can engraft without the risk of immune rejection, eliminating the need for immunosuppression and the associated side effects. Despite this advantage, there are currently more allogeneic than autologous iPSC-based cell therapy products in development due to the cost and complexity of scaling out manufacturing for each patient. In this review, we highlight recent progress toward clinical translation of autologous iPSC-based cell therapies. We also highlight technological advancements that would reduce the cost and complexity of autologous iPSC-based cell therapy production, enabling autologous iPSC-based therapies to become a more commonplace treatment modality for patients. © 2021 The Authors.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Madrid, M., Sumen, C., Aivio, S., & Saklayen, N. (2021). Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges. Current Protocols, 1(3), e88. https://doi.org/10.1002/cpz1.88

MLA 9

Madrid, Marinna, et al. “Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges.” Current Protocols, vol. 1, no. 3, 2021, p. e88. https://doi.org/10.1002/cpz1.88.

Chicago

Madrid, Marinna, Cenk Sumen, Suvi Aivio, and Nabiha Saklayen. 2021. “Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges.” Current Protocols 1 (3): e88. https://doi.org/10.1002/cpz1.88.

Harvard

Madrid, M. et al. (2021) ‘Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges’, Current Protocols, 1(3), p. e88. doi:10.1002/cpz1.88.

IEEE

M. Madrid, C. Sumen, S. Aivio, and N. Saklayen, “Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges,” Current Protocols, vol. 1, no. 3, p. e88, 2021, doi: 10.1002/cpz1.88.

BibTeX

@article{madrid2021autologous,
  title     = {{Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges}},
  author    = {Madrid, Marinna and Sumen, Cenk and Aivio, Suvi and Saklayen, Nabiha},
  journal   = {Current Protocols},
  year      = {2021},
  volume    = {1},
  number    = {3},
  pages     = {e88},
  doi       = {10.1002/cpz1.88},
  url       = {https://doi.org/10.1002/cpz1.88}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201911
202122
20221515
20233535
20242727
20253232
20261414

Its field-weighted citation impact is 1.89: it has been cited 1.89 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • clinical translation
  • patient-specific cell therapy
  • cell therapy manufacturing
  • immunosuppression-free transplantation
  • immune rejection

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Madrid, M., Sumen, C., Aivio, S., & Saklayen, N. (2021). Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges. Current Protocols, 1(3), e88. https://doi.org/10.1002/cpz1.88

How many times has this paper been cited?

126 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Current Protocols: sign in and open the PDF from this page.

Who wrote this paper?

Marinna Madrid, Cenk Sumen, Suvi Aivio, Nabiha Saklayen.

What is the DOI of this paper?

10.1002/cpz1.88, permanently at https://doi.org/10.1002/cpz1.88. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.